Scholar Rock (SRRK) Set to Announce Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Scholar Rock to post earnings of ($0.60) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.01. During the same quarter in the prior year, the business earned ($0.47) earnings per share. On average, analysts expect Scholar Rock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Scholar Rock Trading Up 1.2 %

Shares of SRRK stock traded up $0.33 on Tuesday, hitting $28.00. 355,492 shares of the company’s stock traded hands, compared to its average volume of 1,139,295. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of -12.30 and a beta of 0.47. The company’s fifty day simple moving average is $17.17 and its 200 day simple moving average is $12.73. Scholar Rock has a one year low of $6.76 and a one year high of $35.38. The company has a debt-to-equity ratio of 0.36, a quick ratio of 6.04 and a current ratio of 6.04.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. BMO Capital Markets lifted their price objective on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. HC Wainwright lifted their price target on Scholar Rock from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. JPMorgan Chase & Co. increased their price objective on Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, October 14th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 target price on shares of Scholar Rock in a research note on Monday. Finally, Piper Sandler upped their price objective on shares of Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.29.

Insider Transactions at Scholar Rock

In related news, CFO Edward H. Myles sold 206,240 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $26.56, for a total value of $5,477,734.40. Following the completion of the transaction, the chief financial officer now directly owns 161,088 shares of the company’s stock, valued at $4,278,497.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Scholar Rock news, insider Tracey Sacco sold 30,000 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $25.62, for a total transaction of $768,600.00. Following the completion of the transaction, the insider now owns 49,285 shares of the company’s stock, valued at approximately $1,262,681.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Edward H. Myles sold 206,240 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $26.56, for a total transaction of $5,477,734.40. Following the completion of the sale, the chief financial officer now directly owns 161,088 shares in the company, valued at $4,278,497.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,415,340 shares of company stock valued at $40,666,088. Company insiders own 19.20% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.